## Gudrun Fleischhack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/341672/publications.pdf

Version: 2024-02-01

37 papers 5,208 citations

304743 22 h-index 345221 36 g-index

37 all docs

37 docs citations

37 times ranked

8505 citing authors

#	Article	IF	CITATIONS
1	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. Cancers, 2022, 14, 471.	3.7	9
2	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. Cancers, 2022, 14, 679.	3.7	4
3	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. Cancers, 2022, 14, 126.	3.7	12
4	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
5	Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia, 2021, 35, 2650-2657.	7.2	13
6	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. Cancers, 2021, 13, 1876.	3.7	7
7	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
8	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110
9	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro-Oncology, 2021, 23, 1012-1023.	1.2	19
10	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	2.9	6
11	Functional loss of a noncanonical BCOR–PRC1.1 complex accelerates SHH-driven medulloblastoma formation. Genes and Development, 2020, 34, 1161-1176.	5.9	16
12	Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment. PLoS ONE, 2020, 15, e0227693.	2.5	14
13	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	1.6	58
14	Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. Journal of Neuro-Oncology, 2019, 143, 107-113.	2.9	25
15	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
16	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
17	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
18	Childhood cancer predisposition syndromesâ€"A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200

#	Article	IF	Citations
19	Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. Journal of Neuro-Oncology, 2016, 128, 463-471.	2.9	18
20	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. European Journal of Cancer, 2016, 65, 91-101.	2.8	262
21	Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathologica, 2016, 132, 635-637.	7.7	73
22	Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. Journal of Neuro-Oncology, 2016, 129, 515-524.	2.9	99
23	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
24	Strategies to improve the quality of survival for childhood brain tumour survivors. European Journal of Paediatric Neurology, 2015, 19, 619-639.	1.6	36
25	Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. European Journal of Cancer, 2015, 51, 2634-2642.	2.8	44
26	Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell support: results of the HITREZ 97 multicentre trial. Journal of Neuro-Oncology, 2014, 120, 635-642.	2.9	21
27	High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). Bone Marrow Transplantation, 2014, 49, 370-375.	2.4	58
28	Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastoma—An Experience From the HIT-REZ 1997 & Dournal of Radiation Oncology Biology Physics, 2014, 88, 1019-1024.	0.8	21
29	BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget, 2013, 4, 2080-2095.	1.8	122
30	Nimotuzumab treatment of malignant gliomas. Expert Opinion on Biological Therapy, 2012, 12, 1649-1659.	3.1	53
31	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology, 2011, 13, 669-679.	1.2	149
32	Pharmacokinetics Following Intraventricular Administration of Chemotherapy in Patients with Neoplastic Meningitis. Clinical Pharmacokinetics, 2005, 44, 1-31.	3.5	94
33	Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. British Journal of Cancer, 2001, 84, 1453-1459.	6.4	48
34	Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. Journal of Antimicrobial Chemotherapy, 2001, 47, 841-853.	3.0	49
35	Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of Câ€reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. British Journal of Haematology, 2000, 111, 1093-1102.	2.5	2
36	Treatment of relapsed AML in children. British Journal of Haematology, 1999, 104, 420-421.	2.5	0

#	Article	IF	CITATIONS
37	Cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B: three case reports. Mycoses, 1997, 40, 359-361.	4.0	13